Claims
- 1. A composition for inhibiting photoaging of human skin, comprising a combination of a direct acting MMP inhibitor and at least one of (i) a combination of a UVA blocker and a UVB blocker and (ii) a direct MMP inhibitor, all combined in a topically acceptable carrier.
- 2. A method for inhibiting photoaging of human skin, comprising the daily application of the composition of claim 1 to the skin.
- 3. The composition of claim 1, wherein the direct acting MMP inhibitor is selected from the group consisting of Galardin, Batimastat, and Marimastat, and those disclosed in EP-A1-0 558635 and EP-A1-0 558648, and mixtures thereof.
- 4. The composition of claim 1, wherein the UVA blocker is 4-t-butyl-4′-methoxydibenzoylmethane or a derivative thereof.
- 5. The composition of claim 1, wherein the UVB blocker is an oxybenzone or a methoxycinnamate.
- 6. The composition of claim 1, formulated as a lotion, cream, ointment, water-based liquid, oil-based liquid, or sprayable liquid.
- 7. The composition of claims 1, wherein said composition further comprises at least one additional compound selected from the group consisting of retinoids and tetracycline and derivatives thereof, dermatologically acceptable triazoles and derivatives thereof, a compound that inhibits the cytochrome P-450 mediated-metabolism of retinoic acid, a isoflavone, NAC, FDO, vitamin C, and compatible mixtures thereof.
- 8. A method for inhibiting photoaging of human skin by inhibiting the induction of UV-induced MMP formation in human skin, comprising applying to the skin a composition comprising a combination of a direct acting MMP inhibitor and at least one of (i) a combination of a UVA blocker and a UVB blocker and (ii) a direct MMP inhibitor, in a topically acceptable carrier and applied to said skin.
- 9. A method for inhibiting photoaging of human skin by inhibiting the induction of UV-induced MMP formation in human skin, comprising:
A. applying a composition in the morning with a combination of a direct acting MMP inhibitor and a combination of a UVA blocker and a UVB blocker; and B. apply a composition in the evening with an indirect acting MMP inhibitor.
- 10. The method of claim 9, wherein the direct acting MMP inhibitor is selected from the group consisting of Galardin, Batimastat, and Marimastat, and those disclosed in EP-A1-0 558635 and EP-A1-0 558648, and mixtures thereof.
- 11. The method of claim 9, wherein the indirect MMP inhibitor is selected from the group consisting of retinoids, an isoflavone, NAC, FDO, vitamin C, and compatible mixtures thereof.
- 12. The method of claim 9, wherein said evening composition comprises a retinoid and further comprises at least one additional compound selected from the group consisting of tetracycline and derivatives thereof, dermatologically acceptable triazoles and derivatives thereof, a compound that inhibits the cytochrome P-450 mediated-metabolism of retinoic acid, and compatible mixtures thereof.
- 13. A composition for inhibiting subMED UV-induction of MMPs in human skin, comprising an effective amount of a direct acting MMP inhibitor formulated in a dermatologically acceptable carrier.
- 14. The composition of claim 13, further comprising a UVA blocker and a UVB blocker.
- 15. The composition of claim 14, wherein the UVA blocker is is 4-t-butyl-4′-methoxydibenzoylmethane or a derivative thereof.
- 16. The composition of claim 15, wherein the UVB blocker is an oxybenzone or a methoxycinnamate.
- 17. The composition of claim 13, wherein the composition further comprises a retinoid and the retinoid is retinol, retinoic acid, or a mixture thereof.
- 18. A method for inhibiting subMED UV-induction of MMPs in human skin which comprises providing an effective amount of a direct acting MMP inhibitor formulated in a dermatologically acceptable carrier, and applying the formulation to the skin.
- 19. The method of claim 18, further comprising admixing a UVA blocker and a UVB blocker with said direct acting MMP in said carrier.
- 20. The method of claim 18, wherein the formulation is applied at least once daily to the skin.
- 21. The method of claim 18, wherein the formulation is applied prior to exposure to UV radiation.
- 22. The method of claim 18, wherein said formulation is a lotion, cream, ointment, water-based liquid, or oil-based liquid.
- 23. The method of claim 22, wherein the formulation is sprayable.
RELATED APPLICATIONS
[0001] This application is a division of application 09/615,218, filed Jul. 13, 2000, now U.S. Pat. No. 6,365,630, which is a division of application 09/089,914, filed Jun. 3, 1998, now U.S. Pat. No. 6,130,254, which is a based on provisional applications 60/048,520, filed Jun. 4, 1997 and 60/057,976, filed Sep. 5, 1997.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60048520 |
Jun 1997 |
US |
|
60057976 |
Sep 1997 |
US |
Divisions (2)
|
Number |
Date |
Country |
Parent |
09615218 |
Jul 2000 |
US |
Child |
10114651 |
Apr 2002 |
US |
Parent |
09089914 |
Jun 1998 |
US |
Child |
09615218 |
Jul 2000 |
US |